
Implanted GLP-1 receptor agonist device ITCA 650 rejected by FDA panel due to safety concerns and lack of evidence.


coremsg

An implanted device for delivering the GLP-1 receptor agonist exenatide to people with type 2 diabetes received a unanimous no vote from an FDA advisory panel based on safety and other concerns.

FDA Panel Rejects Implanted GLP1-RA-Dosing Device for T2D

fda-panel-unanimously-rejects-itca-650-device-for-t2d-treatment


FDA Panel Unanimously Rejects ITCA 650 Device for T2D Treatment
